Share this:

Each year about 90,000 men seek treatment for recurrent prostate cancer, and evaluating them for recurrence is a major challenge. Physicians have to wait until a patient’s prostate-specific antigen (PSA) levels rise to a certain level to identify sites of the recurrence.

Now Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C-11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer.

Click here for news release

Animation, b-roll and sound bites with Eugene Kwon, M.D. and Val Lowe, M.D. are available in the downloads.

Expert titles for broadcast cg:
Dr. Eugene Kwon, Mayo Clinic Urologist
Dr. Val Lowe, Mayo Clinic Radiologist

Related Articles

Cancer

New lymphoma therapy helps couple continue their love story

Health & Wellness

(VIDEO) Why more liver donors are needed

Surgery

Your abdominal core: Expert shares tips for protecting a part of the body you may not think about